193 related articles for article (PubMed ID: 24738722)
1. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.
Masclee GM; Coloma PM; de Wilde M; Kuipers EJ; Sturkenboom MC
Aliment Pharmacol Ther; 2014 Jun; 39(11):1321-30. PubMed ID: 24738722
[TBL] [Abstract][Full Text] [Related]
2. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
3. The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital.
Royston C; Caygill C; Charlett A; Bardhan KD
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1365-1373. PubMed ID: 27571366
[TBL] [Abstract][Full Text] [Related]
4. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus.
Holmberg D; Ness-Jensen E; Mattsson F; El-Serag HB; Lagergren J
Eur J Cancer; 2017 Apr; 75():41-46. PubMed ID: 28214656
[TBL] [Abstract][Full Text] [Related]
5. Adam, Eve and the reflux enigma: age and sex differences across the gastro-oesophageal reflux spectrum.
Royston C; Bardhan KD
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):634-639. PubMed ID: 28151751
[TBL] [Abstract][Full Text] [Related]
6. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study.
de Jonge PJ; van Blankenstein M; Looman CW; Casparie MK; Meijer GA; Kuipers EJ
Gut; 2010 Aug; 59(8):1030-6. PubMed ID: 20639249
[TBL] [Abstract][Full Text] [Related]
7. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ;
Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690
[TBL] [Abstract][Full Text] [Related]
8. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
[TBL] [Abstract][Full Text] [Related]
9. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma.
den Hoed CM; van Blankenstein M; Dees J; Kuipers EJ
Br J Cancer; 2011 Jul; 105(2):200-5. PubMed ID: 21673678
[TBL] [Abstract][Full Text] [Related]
10. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis.
Desai TK; Krishnan K; Samala N; Singh J; Cluley J; Perla S; Howden CW
Gut; 2012 Jul; 61(7):970-6. PubMed ID: 21997553
[TBL] [Abstract][Full Text] [Related]
11. Increasing incidence of Barrett's oesophagus in the general population.
van Soest EM; Dieleman JP; Siersema PD; Sturkenboom MC; Kuipers EJ
Gut; 2005 Aug; 54(8):1062-6. PubMed ID: 15857935
[TBL] [Abstract][Full Text] [Related]
12. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
13. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis.
Caygill CP; Reed PI; Johnston BJ; Hill MJ; Ali MH; Levi S
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1355-8. PubMed ID: 10654794
[TBL] [Abstract][Full Text] [Related]
14. Rising incidence of clinically evident Barrett's oesophagus in The Netherlands: a nation-wide registry of pathology reports.
Post PN; Siersema PD; Van Dekken H
Scand J Gastroenterol; 2007 Jan; 42(1):17-22. PubMed ID: 17190757
[TBL] [Abstract][Full Text] [Related]
15. Modelling a population with Barrett's oesophagus from oesophageal adenocarcinoma incidence data.
Van Blankenstein M; Looman CW; Kruijshaar ME; Siersema PD; Kuipers EJ; Bytzer P
Scand J Gastroenterol; 2007 Mar; 42(3):308-17. PubMed ID: 17354109
[TBL] [Abstract][Full Text] [Related]
16. MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma.
Fisher OM; Levert-Mignon AJ; Lord SJ; Lee-Ng KK; Botelho NK; Falkenback D; Thomas ML; Bobryshev YV; Whiteman DC; Brown DA; Breit SN; Lord RV
Br J Cancer; 2015 Apr; 112(8):1384-91. PubMed ID: 25867265
[TBL] [Abstract][Full Text] [Related]
17. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.
Pohl H; Pech O; Arash H; Stolte M; Manner H; May A; Kraywinkel K; Sonnenberg A; Ell C
Gut; 2016 Feb; 65(2):196-201. PubMed ID: 26113177
[TBL] [Abstract][Full Text] [Related]
18. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
[TBL] [Abstract][Full Text] [Related]
19. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study.
Bhat SK; McManus DT; Coleman HG; Johnston BT; Cardwell CR; McMenamin U; Bannon F; Hicks B; Kennedy G; Gavin AT; Murray LJ
Gut; 2015 Jan; 64(1):20-5. PubMed ID: 24700439
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.
Gatenby P; Bhattacharjee S; Wall C; Caygill C; Watson A
World J Gastroenterol; 2016 Dec; 22(48):10592-10600. PubMed ID: 28082811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
